Latest Strategy News

Pure Foods Tasmania has agreed to acquire premium seafood brand Brilliant Food Australia, adding $1.3 million in annual revenue and expanding its national footprint.

Wiseway Group Limited has announced a 12-month on-market share buyback program to repurchase up to 10% of its issued capital, aiming to enhance shareholder returns and support market liquidity.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Many Peaks Minerals has reported significant high-grade gold intercepts from recent diamond drilling at its Ferké project in Côte d’Ivoire, advancing towards a maiden Mineral Resource Estimate planned for early 2026.

eMetals Limited has inked a binding deal to acquire the Mineral Range Tungsten Project in Utah, marking a strategic move into a critical mineral with robust exploration potential. The company is poised to launch a comprehensive exploration program targeting high-grade tungsten deposits in a mining-friendly US jurisdiction.

Buxton Resources has raised approximately A$3 million through a well-supported share placement, aiming to fast-track drilling and exploration across key Australian projects.

Frontier Digital Ventures reported a sharp 18% revenue decline in FY2025 due to shedding low-margin businesses, yet achieved a remarkable 205% jump in EBITDA, signalling a successful pivot to core classifieds in emerging markets.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.

Way2VAT has successfully raised A$2.6 million through a share placement, aiming to repay short-term debt and fund its strategic expansion plans. Investors have shown strong support, agreeing to a six-month escrow on their shares.

Garda Property Group has announced an on-market buy-back of up to 21 million securities starting in April 2026, continuing its capital management strategy without requiring shareholder approval.

Pathkey.AI has secured a significant commercial contract with Imunexus Therapeutics, deploying its AI-driven TrialKey platform to enhance early-phase clinical trial design and capital raising efforts.

Emyria Limited has launched a targeted recruitment campaign in New South Wales to establish its fourth state-based clinical operation, aiming to tap into Australia's largest mental health market amid rising psychological injury claims.